JPH03271215A - Drug-containing granule and dentifrice containing the same - Google Patents
Drug-containing granule and dentifrice containing the sameInfo
- Publication number
- JPH03271215A JPH03271215A JP2071154A JP7115490A JPH03271215A JP H03271215 A JPH03271215 A JP H03271215A JP 2071154 A JP2071154 A JP 2071154A JP 7115490 A JP7115490 A JP 7115490A JP H03271215 A JPH03271215 A JP H03271215A
- Authority
- JP
- Japan
- Prior art keywords
- granule
- water
- granules
- inorganic binder
- dentifrice
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008187 granular material Substances 0.000 title claims abstract description 75
- 239000000551 dentifrice Substances 0.000 title claims abstract description 20
- 229940079593 drug Drugs 0.000 title description 6
- 239000003814 drug Substances 0.000 title description 6
- 239000004615 ingredient Substances 0.000 claims abstract description 28
- 239000011230 binding agent Substances 0.000 claims abstract description 21
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims abstract description 15
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 claims abstract description 12
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 claims abstract description 9
- 239000008119 colloidal silica Substances 0.000 claims abstract description 9
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract description 8
- 229930003427 Vitamin E Natural products 0.000 claims abstract description 4
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims abstract description 4
- 235000019165 vitamin E Nutrition 0.000 claims abstract description 4
- 229940046009 vitamin E Drugs 0.000 claims abstract description 4
- 239000011709 vitamin E Substances 0.000 claims abstract description 4
- 239000002245 particle Substances 0.000 claims description 16
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 6
- QYIXCDOBOSTCEI-UHFFFAOYSA-N alpha-cholestanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 QYIXCDOBOSTCEI-UHFFFAOYSA-N 0.000 claims description 6
- CUFNKYGDVFVPHO-UHFFFAOYSA-N azulene Chemical compound C1=CC=CC2=CC=CC2=C1 CUFNKYGDVFVPHO-UHFFFAOYSA-N 0.000 claims description 6
- FUWUEFKEXZQKKA-UHFFFAOYSA-N beta-thujaplicin Chemical compound CC(C)C=1C=CC=C(O)C(=O)C=1 FUWUEFKEXZQKKA-UHFFFAOYSA-N 0.000 claims description 6
- WMGSQTMJHBYJMQ-UHFFFAOYSA-N aluminum;magnesium;silicate Chemical compound [Mg+2].[Al+3].[O-][Si]([O-])([O-])[O-] WMGSQTMJHBYJMQ-UHFFFAOYSA-N 0.000 claims description 5
- 229960003720 enoxolone Drugs 0.000 claims description 5
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 claims description 4
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 claims description 4
- 229960003260 chlorhexidine Drugs 0.000 claims description 4
- QYIXCDOBOSTCEI-QCYZZNICSA-N (5alpha)-cholestan-3beta-ol Chemical compound C([C@@H]1CC2)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CCCC(C)C)[C@@]2(C)CC1 QYIXCDOBOSTCEI-QCYZZNICSA-N 0.000 claims description 3
- IJALWSVNUBBQRA-UHFFFAOYSA-N 4-Isopropyl-3-methylphenol Chemical compound CC(C)C1=CC=C(O)C=C1C IJALWSVNUBBQRA-UHFFFAOYSA-N 0.000 claims description 3
- TUFYVOCKVJOUIR-UHFFFAOYSA-N alpha-Thujaplicin Natural products CC(C)C=1C=CC=CC(=O)C=1O TUFYVOCKVJOUIR-UHFFFAOYSA-N 0.000 claims description 3
- GUJOJGAPFQRJSV-UHFFFAOYSA-N dialuminum;dioxosilane;oxygen(2-);hydrate Chemical compound O.[O-2].[O-2].[O-2].[Al+3].[Al+3].O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O GUJOJGAPFQRJSV-UHFFFAOYSA-N 0.000 claims description 3
- ZFSXZJXLKAJIGS-UHFFFAOYSA-N halocarban Chemical compound C1=C(Cl)C(C(F)(F)F)=CC(NC(=O)NC=2C=CC(Cl)=CC=2)=C1 ZFSXZJXLKAJIGS-UHFFFAOYSA-N 0.000 claims description 3
- 229950006625 halocarban Drugs 0.000 claims description 3
- NFIDBGJMFKNGGQ-UHFFFAOYSA-N isopropylmethylphenol Natural products CC(C)CC1=CC=CC=C1O NFIDBGJMFKNGGQ-UHFFFAOYSA-N 0.000 claims description 3
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 claims description 3
- 239000001095 magnesium carbonate Substances 0.000 claims description 3
- 229910000021 magnesium carbonate Inorganic materials 0.000 claims description 3
- 229910052901 montmorillonite Inorganic materials 0.000 claims description 3
- ICUTUKXCWQYESQ-UHFFFAOYSA-N triclocarban Chemical compound C1=CC(Cl)=CC=C1NC(=O)NC1=CC=C(Cl)C(Cl)=C1 ICUTUKXCWQYESQ-UHFFFAOYSA-N 0.000 claims description 3
- 229960001325 triclocarban Drugs 0.000 claims description 3
- 229930007845 β-thujaplicin Natural products 0.000 claims description 3
- 239000005995 Aluminium silicate Substances 0.000 claims description 2
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 claims description 2
- 235000012211 aluminium silicate Nutrition 0.000 claims description 2
- 229940024546 aluminum hydroxide gel Drugs 0.000 claims description 2
- SMYKVLBUSSNXMV-UHFFFAOYSA-K aluminum;trihydroxide;hydrate Chemical compound O.[OH-].[OH-].[OH-].[Al+3] SMYKVLBUSSNXMV-UHFFFAOYSA-K 0.000 claims description 2
- 239000000440 bentonite Substances 0.000 claims description 2
- 229910000278 bentonite Inorganic materials 0.000 claims description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 claims description 2
- 239000000378 calcium silicate Substances 0.000 claims description 2
- 229910052918 calcium silicate Inorganic materials 0.000 claims description 2
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 claims description 2
- GDVKFRBCXAPAQJ-UHFFFAOYSA-A dialuminum;hexamagnesium;carbonate;hexadecahydroxide Chemical compound [OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Al+3].[Al+3].[O-]C([O-])=O GDVKFRBCXAPAQJ-UHFFFAOYSA-A 0.000 claims description 2
- 229910001701 hydrotalcite Inorganic materials 0.000 claims description 2
- 229960001545 hydrotalcite Drugs 0.000 claims description 2
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 claims description 2
- 239000000606 toothpaste Substances 0.000 claims description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims 1
- 239000000347 magnesium hydroxide Substances 0.000 claims 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 claims 1
- 229940034610 toothpaste Drugs 0.000 claims 1
- 239000007921 spray Substances 0.000 abstract description 10
- 238000000034 method Methods 0.000 abstract description 8
- 238000002156 mixing Methods 0.000 abstract description 7
- 210000000214 mouth Anatomy 0.000 abstract description 7
- 208000002925 dental caries Diseases 0.000 abstract description 5
- 239000006071 cream Substances 0.000 abstract description 2
- 238000001125 extrusion Methods 0.000 abstract description 2
- 239000002674 ointment Substances 0.000 abstract description 2
- 239000000126 substance Substances 0.000 abstract description 2
- 230000000857 drug effect Effects 0.000 abstract 3
- 208000010266 Aggressive Periodontitis Diseases 0.000 abstract 1
- 230000004807 localization Effects 0.000 abstract 1
- 201000006727 periodontosis Diseases 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 239000002002 slurry Substances 0.000 description 6
- -1 alkyl phosphoric acids Chemical class 0.000 description 5
- 238000005469 granulation Methods 0.000 description 5
- 230000003179 granulation Effects 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- 208000002064 Dental Plaque Diseases 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 230000001680 brushing effect Effects 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 208000028169 periodontal disease Diseases 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 150000003722 vitamin derivatives Chemical class 0.000 description 3
- 241000628997 Flos Species 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000019700 dicalcium phosphate Nutrition 0.000 description 2
- HNPSIPDUKPIQMN-UHFFFAOYSA-N dioxosilane;oxo(oxoalumanyloxy)alumane Chemical compound O=[Si]=O.O=[Al]O[Al]=O HNPSIPDUKPIQMN-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 235000011007 phosphoric acid Nutrition 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000005201 scrubbing Methods 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 2
- 229920005992 thermoplastic resin Polymers 0.000 description 2
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 2
- XGRSAFKZAGGXJV-UHFFFAOYSA-N 3-azaniumyl-3-cyclohexylpropanoate Chemical compound OC(=O)CC(N)C1CCCCC1 XGRSAFKZAGGXJV-UHFFFAOYSA-N 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- WJLVQTJZDCGNJN-UHFFFAOYSA-N Chlorhexidine hydrochloride Chemical compound Cl.Cl.C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 WJLVQTJZDCGNJN-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 108010001682 Dextranase Proteins 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 241000241413 Propolis Species 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 229910021536 Zeolite Inorganic materials 0.000 description 1
- 239000003082 abrasive agent Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 125000004442 acylamino group Chemical class 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229910000323 aluminium silicate Inorganic materials 0.000 description 1
- 229940024545 aluminum hydroxide Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229960003563 calcium carbonate Drugs 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- JUNWLZAGQLJVLR-UHFFFAOYSA-J calcium diphosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])(=O)OP([O-])([O-])=O JUNWLZAGQLJVLR-UHFFFAOYSA-J 0.000 description 1
- 229940043256 calcium pyrophosphate Drugs 0.000 description 1
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 description 1
- 239000004075 cariostatic agent Substances 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 229960001927 cetylpyridinium chloride Drugs 0.000 description 1
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 1
- 229960004504 chlorhexidine hydrochloride Drugs 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000019821 dicalcium diphosphate Nutrition 0.000 description 1
- 229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 1
- YVIGPQSYEAOLAD-UHFFFAOYSA-L disodium;dodecyl phosphate Chemical compound [Na+].[Na+].CCCCCCCCCCCCOP([O-])([O-])=O YVIGPQSYEAOLAD-UHFFFAOYSA-L 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 108010000165 exo-1,3-alpha-glucanase Proteins 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 210000004195 gingiva Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910000358 iron sulfate Inorganic materials 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- GVALZJMUIHGIMD-UHFFFAOYSA-H magnesium phosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O GVALZJMUIHGIMD-UHFFFAOYSA-H 0.000 description 1
- 239000004137 magnesium phosphate Substances 0.000 description 1
- 229910000157 magnesium phosphate Inorganic materials 0.000 description 1
- 229960002261 magnesium phosphate Drugs 0.000 description 1
- 235000010994 magnesium phosphates Nutrition 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 230000007406 plaque accumulation Effects 0.000 description 1
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 229940069949 propolis Drugs 0.000 description 1
- 239000001054 red pigment Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000011775 sodium fluoride Substances 0.000 description 1
- 235000013024 sodium fluoride Nutrition 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- AQMNWCRSESPIJM-UHFFFAOYSA-M sodium metaphosphate Chemical compound [Na+].[O-]P(=O)=O AQMNWCRSESPIJM-UHFFFAOYSA-M 0.000 description 1
- 229960004711 sodium monofluorophosphate Drugs 0.000 description 1
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000008646 thermal stress Effects 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 230000009974 thixotropic effect Effects 0.000 description 1
- YUOWTJMRMWQJDA-UHFFFAOYSA-J tin(iv) fluoride Chemical compound [F-].[F-].[F-].[F-].[Sn+4] YUOWTJMRMWQJDA-UHFFFAOYSA-J 0.000 description 1
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 description 1
- 229960000401 tranexamic acid Drugs 0.000 description 1
- 235000019731 tricalcium phosphate Nutrition 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000003232 water-soluble binding agent Substances 0.000 description 1
- 239000010457 zeolite Substances 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Landscapes
- Cosmetics (AREA)
Abstract
Description
【発明の詳細な説明】
[産業上の利用分野コ
本発明は、口腔用薬効成分を配合した顆粒剤及びこれを
含有する歯磨剤に関する。更に詳しくは、う蝕、歯周疾
患の好発部位である歯と歯の間、歯と歯肉の隙間に口腔
用薬効成分を直接作用させることのできる顆粒剤及びこ
れを含有する歯磨剤に関する。DETAILED DESCRIPTION OF THE INVENTION [Field of Industrial Application] The present invention relates to a granule containing a medicinal ingredient for the oral cavity and a dentifrice containing the same. More specifically, the present invention relates to granules that can directly apply oral medicinal ingredients to the gaps between teeth and between teeth and gums, which are areas where caries and periodontal disease are most likely to occur, and to dentifrices containing the same.
[従来の技術]
歯磨剤に顆粒を配合するという技術は従来知られており
、顆粒の結合剤として、ワックス、熱可塑性樹脂、エチ
ルセルロース等の有機結合剤を使用した歯磨剤が多数特
許出願されている。このような歯磨剤としては、例えば
審美性と製造のしやすさを目的としたもの(特開昭48
−013558号公報特開昭48−019738号公報
、特開昭50−081594号公報特開昭62−116
506号公報、米国特許第3929987号明細書、米
国特許第4202878号明細書、米国特許第4376
762号明細書、米国特許第4376763号明細書、
米国特許第4440877号明細書、米国特許第466
3152号明細書)、顆粒に色素、香料等を含有させ、
歯磨終了時のインジケーターを目的としたもの(特開昭
60−016913号公報、特開昭62−116506
号公報、特開昭63−250314号公報、ベルギー特
許第803155号明細書)、顆粒に薬効成分を含有さ
せ、その薬剤の安定化を図ったもの(特開昭48−01
9738号公報、特開昭49−132249号公報、特
開昭54080429号公報)等が挙げられる。[Prior Art] The technology of blending granules into dentifrices has been known in the past, and numerous patent applications have been filed for dentifrices that use organic binders such as wax, thermoplastic resins, and ethyl cellulose as binders for granules. There is. Examples of such dentifrices include those aimed at aesthetics and ease of manufacture (Japanese Patent Laid-Open No. 48
-013558 Publication JP-A-48-019738, JP-A-50-081594, JP-A-62-116
No. 506, US Pat. No. 3,929,987, US Pat. No. 4,202,878, US Pat. No. 4,376
No. 762 specification, U.S. Patent No. 4,376,763 specification,
U.S. Patent No. 4,440,877, U.S. Patent No. 466
3152 specification), the granules contain pigments, fragrances, etc.
For the purpose of an indicator when tooth brushing is completed (Japanese Patent Application Laid-Open No. 60-016913, JP-A No. 62-116506)
JP-A No. 63-250314, Belgian Patent No. 803155), granules containing medicinal ingredients to stabilize the drug (JP-A No. 48-01)
9738, JP-A-49-132249, JP-A-54080429), and the like.
一方、口腔内の2大疾患であるう蝕、歯周疾患は、歯と
歯の間、溝、歯と歯肉の隙間から生ずることが知られて
いる。例えば、臼歯部のう蝕の90%以上が裂溝部より
生ずる。また、歯と歯肉の間の歯間ポケットより炎症が
起こると言われている。On the other hand, it is known that caries and periodontal disease, which are two major diseases in the oral cavity, occur in the spaces between teeth, grooves, and gaps between teeth and gums. For example, more than 90% of caries in the molar region originates from the fissure region. It is also said that inflammation occurs in the interdental pockets between the teeth and gums.
これらの疾患の予防のため、歯間フロスによる歯垢の除
去、種々の薬剤による歯垢蓄積の阻害又は歯質・歯肉の
強化などが行なわれている。To prevent these diseases, methods include removing dental plaque with interdental floss, inhibiting plaque accumulation with various drugs, and strengthening tooth structure and gingiva.
[発明が解決しようとする課題]
しかしながら、歯間フロスはその取り扱いにある程度の
技術と時間を要し、また薬剤を使用する場合も、上記の
ような隙間には歯垢が堆積していたり、隙間の特有な形
状のため薬剤の浸透が困難であり、充分にその効果を発
揮することができないという欠点があった。[Problems to be Solved by the Invention] However, interdental floss requires a certain amount of skill and time to handle, and even when using chemicals, dental plaque may accumulate in the gaps as mentioned above. Due to the unique shape of the gap, it is difficult for the drug to penetrate and the drug cannot fully exert its effect.
[課題を解決するための手段]
かかる実情において、本発明者らはう蝕や歯周疾患の好
発部位である歯と歯の間や歯と歯肉の隙間に薬効成分を
直接作用させるための剤型について鋭意研究を行なった
結果、薬効成分を配合した水不溶性の結合剤を造粒して
得られる、一定の大きさと強度を有する顆粒を配合した
歯磨剤が、該要件を満たすことを見出し、本発明を完成
した。[Means for Solving the Problems] Under these circumstances, the present inventors have developed a method for directly applying medicinal ingredients to the spaces between teeth and between teeth and gums, which are the areas where caries and periodontal diseases often occur. As a result of intensive research into dosage forms, we discovered that a dentifrice containing granules of a certain size and strength obtained by granulating a water-insoluble binder containing medicinal ingredients satisfies these requirements. , completed the invention.
すなわち本発明は、水不溶性無機結合剤及び口腔用薬効
成分を含有し、50〜500JjMの粒子径を有し、顆
粒1個当り0.1〜10gの荷重を加えたときに崩壊す
る顆粒剤及びこれを含有する歯磨剤を提供するものであ
る。That is, the present invention provides granules that contain a water-insoluble inorganic binder and an oral medicinal ingredient, have a particle size of 50 to 500 JjM, and disintegrate when a load of 0.1 to 10 g is applied to each granule; A dentifrice containing this is provided.
本発明の顆粒剤に用いられる水不溶性無機結合剤として
は、例えばコロイダルシリカ、メタケイ酸アルミン酸マ
グネシウム、ベントナイト、モンモリロナイト、カオリ
ン、合成ケイ酸アルミニウム、ケイ酸カルシウム、水酸
化アルミニウムゲル、アルミナゾル、炭酸マグネシウム
、合成ヒドロタルサイト、酸化マグネシウム、水酸化ナ
トリウム等が挙げられる。これらは単独で、又は2種以
上を組み合わせて使用できる。これらの無機結合剤を使
用し、噴霧造粒して顆粒剤を製造する場合、スラリー状
態でチキソトロピックな性質を有するものが好ましく、
特に、メタケイ酸アルミン酸マグネシウムとコロイダル
シリカとの組み合わせ、合成ケイ酸アルミニウムとコロ
イダルシリカとの組み合わせ等が好ましい。これらの無
機結合剤で造粒した顆粒剤は、有機結合剤で造粒した場
合と異なり、一定の荷重、例えばブラシのブリッスルの
圧力がかかった場合、−気に崩壊するという特徴を有し
ており、薬剤を局所(隙間)で効率よく作用させること
ができる。また、この顆粒剤は水分を含有しても隙間に
到達できるだけの固さを保持し、この固さは無機結合剤
の種類、組み合わせ、配合量、顆粒の製造条件等によっ
て変化させることができる。かかる無機結合剤の配合量
は、その他の成分によって影響を受け、その成分が噴霧
に対してダイラタントな悪い影響を及ぼす場合、その成
分に対して30重量%以上とすることか好ましい。Examples of water-insoluble inorganic binders used in the granules of the present invention include colloidal silica, magnesium aluminate metasilicate, bentonite, montmorillonite, kaolin, synthetic aluminum silicate, calcium silicate, aluminum hydroxide gel, alumina sol, and magnesium carbonate. , synthetic hydrotalcite, magnesium oxide, sodium hydroxide, and the like. These can be used alone or in combination of two or more. When using these inorganic binders to produce granules by spray granulation, it is preferable that they have thixotropic properties in a slurry state.
Particularly preferred are a combination of magnesium aluminate metasilicate and colloidal silica, a combination of synthetic aluminum silicate and colloidal silica, and the like. Granules granulated with these inorganic binders, unlike those granulated with organic binders, have the characteristic that they disintegrate when a certain load is applied, such as the pressure of the bristles of a brush. This allows the drug to act efficiently locally (in spaces). Further, even if this granule contains water, it maintains enough hardness to reach the gaps, and this hardness can be changed depending on the type, combination, amount of inorganic binder, manufacturing conditions of the granule, etc. The blending amount of such an inorganic binder is influenced by other components, and if that component has a dilatant negative effect on spraying, it is preferably 30% by weight or more based on that component.
なお、上記水不溶性無機結合剤以外の結合剤を本発明の
効果を損なわない範囲で添加することもできるが、水溶
性結合剤を配合することは顆粒強度の低下を招き、好ま
しくない。Incidentally, binders other than the water-insoluble inorganic binder described above may be added within a range that does not impair the effects of the present invention, but blending a water-soluble binder is not preferable because it causes a decrease in granule strength.
本発明の顆粒剤に配合される口腔用薬効成分としては、
口腔領域で使用されるものであればよく、特に限定され
るものではないが、例えば虫歯予防剤、抗微生物剤、ビ
タミン、酵素、抗炎症剤等が挙げられ、具体的にはフッ
化ナトリウム、フッ化錫、モノフルオロリン酸ナトリウ
ム、ビタミンE1ビタミンC1デキストラナーゼ、ムタ
ナーゼ、塩化ナトリウム、グリチルレチン酸、アズレン
、β−グリチルレチン酸、ジヒドロコレステロール、ク
ロルヘキシジン、エピジヒドロコレステロール、イソプ
ロピルメチルフェノール、トリクロロカルバニリド、ハ
ロカルバン、ヒノキチオール、アラントイン、トラネキ
サム酸、プロポリス、塩化セチルピリジニウム等が挙げ
られ、これらは単独で、又は二種以上を組み合わせて使
用できる。これらの薬効成分のうち、水溶性のものを含
有する顆粒をO/W系の歯磨剤に配合する場合、歯磨基
剤への溶出を防止するため、噴霧造粒後、顆粒を熱可塑
性樹脂、ワックス等で二次加工する必要がある。The oral medicinal ingredients contained in the granules of the present invention include:
It may be used as long as it is used in the oral cavity, and examples include anti-caries agents, antimicrobial agents, vitamins, enzymes, anti-inflammatory agents, etc., and specific examples include sodium fluoride, Tin fluoride, sodium monofluorophosphate, vitamin E1 vitamin C1 dextranase, mutanase, sodium chloride, glycyrrhetinic acid, azulene, β-glycyrrhetinic acid, dihydrocholesterol, chlorhexidine, epidihydrocholesterol, isopropylmethylphenol, trichlorocarbanilide , halocarban, hinokitiol, allantoin, tranexamic acid, propolis, cetylpyridinium chloride, etc., and these can be used alone or in combination of two or more. When blending granules containing water-soluble among these medicinal ingredients into an O/W type dentifrice, in order to prevent elution into the dentifrice base, the granules are mixed with thermoplastic resin, It is necessary to perform secondary processing using wax, etc.
従って、コスト等の点からは水に不溶性又は難溶性の薬
効成分を使用することが好ましい。このような成分の具
体例としては、アズレン、ビタミンE1β−グリチルレ
チン酸、ジヒドロコレステロール、クロルヘキシジン、
エピジヒドロコレステロール、イソプロピルメチルフェ
ノール、トリクロロカルバニリド、ハロカルバン、ヒノ
キチオール等が挙げられる。Therefore, from the viewpoint of cost and the like, it is preferable to use medicinal ingredients that are insoluble or poorly soluble in water. Specific examples of such ingredients include azulene, vitamin E1β-glycyrrhetinic acid, dihydrocholesterol, chlorhexidine,
Examples include epidihydrocholesterol, isopropylmethylphenol, trichlorocarbanilide, halocarban, and hinokitiol.
本発明の顆粒剤には、通常歯磨剤に研磨剤として使用さ
れる水不溶性粉末材料を配合することもできる。水不溶
性粉末材料としては、第ニリン酸カルシウム、第三リン
酸カルシウム、不溶性メタリン酸ナトリウム、シリカ、
水酸化アルミニウム、リン酸マグネシウム、炭酸カルシ
ウム、ピロリン酸カルシウム、ゼオライト、複合アルミ
ノケイ酸塩、炭酸マグネシウム、ベンガラ、硫酸カルシ
ウム等が挙げられる。The granules of the present invention can also contain water-insoluble powder materials that are commonly used as abrasives in dentifrices. Water-insoluble powder materials include dibasic calcium phosphate, tribasic calcium phosphate, insoluble sodium metaphosphate, silica,
Examples include aluminum hydroxide, magnesium phosphate, calcium carbonate, calcium pyrophosphate, zeolite, composite aluminosilicate, magnesium carbonate, red iron sulfate, and calcium sulfate.
本発明の顆粒剤は、例えば噴霧造粒法、押出し造粒法等
により製造することができるが、特に噴霧造粒法により
製造するのが好ましい。噴霧造粒法により製造すると、
顆粒形状がほとんど真球となり、歯を傷つける恐れが少
なく、また、製造後の取り扱いも容易である。The granules of the present invention can be produced, for example, by a spray granulation method, an extrusion granulation method, etc., but it is particularly preferably produced by a spray granulation method. When manufactured by spray granulation method,
The granule shape is almost perfectly spherical, so there is little risk of damaging teeth, and it is easy to handle after production.
本発明の顆粒剤の調製に際しては、その粒径の調整が必
要である。すなわち、口腔内の歯と歯の間や歯と歯肉の
間の隙間に入りゃすい粒径にする必要がある。顆粒剤の
粒径は50〜500Js1特に100〜400uIR1
更に100〜300JIIRの範囲が好ましい。粒径の
測定は、走査型電子顕微鏡を用いて行えばよい。粒径が
50JEr1未満では上記隙間等へほとんど侵入せず、
500.を超えると口腔内で異物感として触知され、製
品上好ましくない。When preparing the granules of the present invention, it is necessary to adjust the particle size. That is, the particle size needs to be such that it can easily enter the gaps between the teeth in the oral cavity or between the teeth and the gums. The particle size of granules is 50-500Js1, especially 100-400uIR1
Further, a range of 100 to 300 JIIR is preferred. The particle size may be measured using a scanning electron microscope. If the particle size is less than 50 JEr1, it will hardly penetrate into the above gaps, etc.
500. If it exceeds this, it will be felt as a foreign body sensation in the oral cavity, which is not desirable for the product.
また、顆粒剤の強度も重要であり、顆粒上個当たり0.
1〜10gの荷重を加えたときに崩壊する強度であるこ
とが必要である。顆粒が0.1g未満の荷重で崩壊する
場合、隙間に堆積した歯垢の中に潜り込むことができず
、隙間底部に侵入する前に崩壊してしまい、薬効成分を
直接作用させることができない。また、顆粒が10gを
超える荷重でも崩壊しない場合、通常の1〜5分間のブ
ラッシングでは崩壊せず、歯と歯の間や歯と歯肉の間に
挟まってしまい、薬効成分の効果を発揮させることがで
きない。In addition, the strength of the granules is also important, with 0.0% per granule.
It needs to have a strength that allows it to collapse when a load of 1 to 10 g is applied. If the granules disintegrate under a load of less than 0.1 g, they will not be able to penetrate into the dental plaque deposited in the gaps, and will disintegrate before entering the bottom of the gaps, making it impossible for the medicinal ingredients to act directly. In addition, if the granules do not disintegrate even under a load of more than 10g, they will not disintegrate after normal brushing for 1 to 5 minutes and may become stuck between teeth or between teeth and gums, preventing the medicinal ingredients from exerting their effects. I can't.
顆粒の粒径及び強度の調整は、水不溶性無機結合剤の種
類、組み合わせ及び配合量並びに顆粒の製造条件の選択
により行なうことができる。The particle size and strength of the granules can be adjusted by selecting the type, combination and amount of the water-insoluble inorganic binder and the granule manufacturing conditions.
このようにして得られた本発明の顆粒剤は、水分を含有
する種々の組成物、例えばクリーム、軟膏等にも配合す
ることができるか、特に歯磨剤に配合するのが好適であ
る。The granules of the present invention thus obtained can be incorporated into various water-containing compositions, such as creams and ointments, and are particularly preferably incorporated into dentifrices.
本発明の顆粒剤を歯磨中に配合する場合は、その配合量
は歯磨中に1〜50重量%、特に3〜30重量%の範囲
であるのが好ましい。歯磨剤の調製は常法に従って行な
われ、通常の歯磨に使用されるその他の成分、例えば粘
結剤、界面活性剤、甘味料、香料、水等を配合し得るほ
か、顆粒外部にも薬効成分を配合することができる。具
体的には、粘結剤としては、カルボキシメチルセルロー
スナトリウム、ポリアクリル酸ナトリウム、ヒドロキシ
エチルセルロース、増粘性シリカ、モンモリロナイト、
カラギーナン、アルヂン酸ナトリウム、グアガム、ペク
チン等が使用でき、界面活性剤としては、アシルグルタ
ミン酸ナトリウム、アシルサルコシン酸ナトリウム等の
アシルアミノ酸の塩類、ラウリルリン酸ナトリウム等の
アルキルリン酸の塩類、蔗糖脂肪酸エステル、ソルビタ
ン脂肪酸エステル、ポリオキシエチレン脂肪酸エステル
等が使用でき、薬効成分としては、前記の顆粒中に配合
し得るものが水溶性、水不溶性を問わず使用できる。When the granules of the present invention are incorporated into toothbrushing, the amount thereof is preferably in the range of 1 to 50% by weight, particularly 3 to 30% by weight. Dentifrices are prepared according to conventional methods, and other ingredients used in normal toothpastes, such as binders, surfactants, sweeteners, fragrances, water, etc., may be added, and medicinal ingredients may also be added to the outside of the granules. can be blended. Specifically, the binder includes sodium carboxymethyl cellulose, sodium polyacrylate, hydroxyethyl cellulose, thickening silica, montmorillonite,
Carrageenan, sodium aldinate, guar gum, pectin, etc. can be used, and as surfactants, salts of acylamino acids such as sodium acylglutamate and sodium acylsarcosinate, salts of alkyl phosphoric acids such as sodium lauryl phosphate, and sucrose fatty acid esters. , sorbitan fatty acid ester, polyoxyethylene fatty acid ester, etc. can be used, and as medicinal ingredients, those that can be blended into the above-mentioned granules can be used regardless of whether they are water-soluble or water-insoluble.
[実施例]
以下、実施例を挙げて更に詳細に説明するが、本発明は
これらに限定されるものではない。[Examples] Hereinafter, the present invention will be explained in more detail by giving examples, but the present invention is not limited thereto.
実施例1
固形分として、合成ケイ酸アルミニウムを89重量部、
無水ケイ酸(コロイダルシリカ)を10重量部及びβ−
グリチルレチン酸を1重量部含有する水スラリー(水の
含有量は約60%)を、攪拌ミキサーで120分攪拌混
合した後、噴霧造粒機により顆粒剤を製造した。この顆
粒剤全量の99%が粒径50〜500−であった。Example 1 89 parts by weight of synthetic aluminum silicate as solid content,
10 parts by weight of silicic anhydride (colloidal silica) and β-
A water slurry containing 1 part by weight of glycyrrhetinic acid (water content: approximately 60%) was stirred and mixed for 120 minutes using a stirring mixer, and then granules were produced using a spray granulator. 99% of the total amount of the granules had a particle size of 50-500.
この粒径範囲の顆粒をとりだし、熱応力分析装置(セイ
コー株式会社製、 5S−10)で荷重(LOAD=2
g/m1n)をかけ、顆粒1個当りの崩壊時の荷重を
測定し、10回の測定値の平均を顆粒強度とした。Granules in this particle size range were taken out and subjected to a load (LOAD = 2) using a thermal stress analyzer (Seiko Corporation, 5S-10).
g/m1n), the load at the time of collapse per granule was measured, and the average of 10 measurements was taken as the granule strength.
この結果、この顆粒の強度は、4.15g/個であった
。As a result, the strength of the granules was 4.15 g/piece.
実施例2
固形分として、炭酸カルシウムを60重量部、メタケイ
酸アルミン酸マグネシウムを28重量部、無水ケイ酸(
コロイダルシリカ)を10重量部、酸化チタンを1重量
部及び塩酸クロルヘキシジンを1重量部含有する水スラ
リー(水の含有量は約60%)を、攪拌ミキサーで12
0分攪拌混合した後、噴霧造粒機により顆粒剤を製造し
た。この顆粒剤全量の99%が粒径50〜500−であ
った。Example 2 As solid contents, 60 parts by weight of calcium carbonate, 28 parts by weight of magnesium aluminate metasilicate, and silicic anhydride (
A water slurry (water content approximately 60%) containing 10 parts by weight of colloidal silica, 1 part by weight of titanium oxide, and 1 part by weight of chlorhexidine hydrochloride was mixed with a stirring mixer for 12 hours.
After stirring and mixing for 0 minutes, granules were produced using a spray granulator. 99% of the total amount of the granules had a particle size of 50-500.
この顆粒剤について、実施例1と同様にして顆粒強度を
測定したところ、5.16g/個であった。Regarding this granule, the granule strength was measured in the same manner as in Example 1 and found to be 5.16 g/piece.
実施例3
固形分として、合成ケイ酸アルミニウムを98重量部、
界面活性剤を1重量部及びビタミンEを1重量部含有す
る水スラリー(水の含有量は約60%)を、ホモミキサ
ーで30分混合した後、噴霧造粒機により顆粒剤を製造
した。この顆粒剤全量の99%が粒径100〜300μ
であった。Example 3 98 parts by weight of synthetic aluminum silicate as solid content,
A water slurry containing 1 part by weight of a surfactant and 1 part by weight of vitamin E (water content: about 60%) was mixed for 30 minutes using a homomixer, and then granules were produced using a spray granulator. 99% of the total amount of this granule has a particle size of 100 to 300μ
Met.
この顆粒剤について、実施例1と同様にして顆粒強度を
測定したところ、2.83g/個であった。Regarding this granule, the granule strength was measured in the same manner as in Example 1 and found to be 2.83 g/piece.
比較例1
固形分として、リン酸水素カルシウムを50重量部、合
成ケイ酸アルミニウムを49重量部及び酸化チタンを1
重量部含有する水スラリー(水の含有量は約60%)を
、攪拌ミキサーで120分攪拌混合した後、噴霧造粒機
により顆粒剤を製造した。この顆粒剤全量の99%が粒
径50〜500μであった。Comparative Example 1 As solid contents, 50 parts by weight of calcium hydrogen phosphate, 49 parts by weight of synthetic aluminum silicate, and 1 part by weight of titanium oxide
A water slurry containing parts by weight (water content: approximately 60%) was stirred and mixed for 120 minutes using a stirring mixer, and then granules were produced using a spray granulator. 99% of the total amount of the granules had a particle size of 50 to 500μ.
この顆粒剤について、実施例1と同様にして顆粒強度を
測定したところ、2.04g/個であった。Regarding this granule, the granule strength was measured in the same manner as in Example 1 and found to be 2.04 g/piece.
比較例2
固形分と(て、合成ケイ酸アルミニウムを97重量部、
メトローズ(有機結合剤)を2重量部及びβ−グリチル
レチン酸を1重量部を含有する水スラリー(水の含有量
は約60%)を、攪拌ミキサーで120分攪拌混合した
後、噴霧造粒機により顆粒剤を製造した。この顆粒剤全
量の99%が粒径100〜300−であった。Comparative Example 2 Solid content (97 parts by weight of synthetic aluminum silicate,
A water slurry (water content approximately 60%) containing 2 parts by weight of Metrose (organic binder) and 1 part by weight of β-glycyrrhetinic acid was stirred and mixed for 120 minutes using a stirring mixer, and then mixed using a spray granulator. Granules were produced. 99% of the total amount of the granules had a particle size of 100-300.
この顆粒剤について、実施例1と同様にして顆粒強度を
測定したところ、0.07g/個であった。Regarding this granule, the granule strength was measured in the same manner as in Example 1 and found to be 0.07 g/piece.
実施例4
実施例1〜3又は比較例1もしくは2で得られた顆粒剤
を用い、次に示す組成の歯磨剤を調製した。Example 4 Using the granules obtained in Examples 1 to 3 or Comparative Example 1 or 2, a dentifrice having the following composition was prepared.
顆粒剤
グリセリン
ソルビット液
(重量%)
15.0
010
30、O
カルボキシメチルセルロース
ナトリウム
サッカリンナトリウム
メチルパラベン
香料
0
0.1
0.1
0.8
計
100.0
これらの歯磨剤を使用して、薬効成分の局所到達量を以
下の方法で測定した。Granule glycerin sorbitol solution (wt%) 15.0 010 30, O Sodium carboxymethyl cellulose Sodium saccharin Methyl paraben Flavor 0 0.1 0.1 0.8 Total 100.0 Use these dentifrices to deliver medicinal ingredients locally The amount was measured by the following method.
すなわち、直径7mm、長さ80 mmのガラス管を図
1のように接着し、歯の隙間モデルを作製した。That is, glass tubes with a diameter of 7 mm and a length of 80 mm were glued together as shown in Figure 1 to create a tooth gap model.
これに人口歯垢(赤色顔料の割合の高い口紅、花王株式
会社製、ソフィーナ213)を隙間部に厚さ1.0mm
以上になるようにむらなく塗布した。これを歯ブラシ(
ナイロン毛9毛先径200.)のみを用いてスクラビン
グ法によりブラッシングを行ない、人工歯垢を取り除い
た。次いで、歯磨剤2gをこの歯ブラシに精密に計り取
り、スクラビング法で人工歯垢の赤色が完全に消滅する
までブラッシングした。隙間部分を蒸留水100m11
で洗浄した後、ここに残存する薬効成分を抽出し、その
量を高速液体クロマトグラフィーで測定し、局所停滞量
(題)とした。Then apply artificial dental plaque (lipstick with a high proportion of red pigment, Sofina 213, manufactured by Kao Corporation) to a thickness of 1.0 mm in the gap.
It was applied evenly to achieve the above results. Add this to your toothbrush (
Nylon bristles 9 bristles diameter 200. ) was used to remove artificial plaque by brushing using the scrubbing method. Next, 2 g of dentifrice was precisely weighed onto the toothbrush, and the tooth was brushed using a scrubbing method until the red color of the artificial plaque completely disappeared. Fill the gap with 100ml of distilled water
After washing with water, the remaining medicinal ingredients were extracted, and the amount was measured using high performance liquid chromatography, which was defined as the local stagnation amount (title).
なお、抽出は、実施例1及び比較例2の薬効成分(β−
グリチルレチン酸)については0.0025Mリン酸酸
性メタノール水溶液(75v/v%)、実施例2の薬効
成分(塩酸クロロヘキシジン)については10mMラウ
リル硫酸ナトリウム含有アセトニトリル10.05Mリ
ン酸緩衝液(60/40) 、実施例3の薬効成分(ビ
タミンE)についてはメタノールを用いて行なった。In addition, the extraction was performed on the medicinal ingredient (β-
0.0025M phosphoric acid acidic methanol aqueous solution (75v/v%) for glycyrrhetinic acid), and acetonitrile 10.05M phosphate buffer containing 10mM sodium lauryl sulfate (60/40) for the medicinal ingredient of Example 2 (chlorohexidine hydrochloride). As for the medicinal ingredient (vitamin E) in Example 3, methanol was used.
この結果を表1に示す。The results are shown in Table 1.
実験例1
実施例1の顆粒剤と同じ組成の顆粒剤を、製造条件を変
えて試作し、篩別することにより、種々の平均粒径(2
0Q、501s、 100uIR,2004,300,
。Experimental Example 1 Granules having the same composition as the granules of Example 1 were produced by changing the manufacturing conditions, and by sieving, various average particle diameters (2
0Q, 501s, 100uIR, 2004, 300,
.
400u11及び500m)の顆粒剤を得た。それぞれ
の顆粒剤を用い、表1の組成の歯磨剤を調製し、実施例
4と同様にしてβ−グリチルレチン酸の局所停滞量を測
定した。Granules of 400 u11 and 500 m) were obtained. A dentifrice having the composition shown in Table 1 was prepared using each of the granules, and the local retention amount of β-glycyrrhetinic acid was measured in the same manner as in Example 4.
この結果を表2に示す。The results are shown in Table 2.
充分にその薬用効果を発揮させることができる。It is possible to fully exhibit its medicinal effects.
図1は、実施例において薬効成分の局所停滞量の測定に
用いた歯の隙間モデルを示す図面である。
以上FIG. 1 is a drawing showing a tooth gap model used in the measurement of the local stagnation amount of medicinal ingredients in Examples. that's all
Claims (7)
、50〜500μmの粒子径を有し、顆粒1個当り0.
1〜10gの荷重を加えたときに崩壊する顆粒剤。(1) Contains a water-insoluble inorganic binder and an oral medicinal ingredient, has a particle size of 50 to 500 μm, and has a particle diameter of 0.000 μm per granule.
Granules that disintegrate when a load of 1 to 10 g is applied.
ケイ酸アルミン酸マグネシウム、ベントナイト、モンモ
リロナイト、カオリン、合成ケイ酸アルミニウム、ケイ
酸カルシウム、水酸化アルミニウムゲル、アルミナゾル
、炭酸マグネシウム、合成ヒドロタルサイト、酸化マグ
ネシウム及び水酸化ナトリウムからなる群より選ばれる
1種又は2種以上である請求項1記載の顆粒剤。(2) The water-insoluble inorganic binder is colloidal silica, magnesium aluminate metasilicate, bentonite, montmorillonite, kaolin, synthetic aluminum silicate, calcium silicate, aluminum hydroxide gel, alumina sol, magnesium carbonate, synthetic hydrotalcite, oxidized The granule according to claim 1, which is one or more selected from the group consisting of magnesium and sodium hydroxide.
とコロイダルシリカの組み合わせ又はメタケイ酸アルミ
ン酸マグネシウムとコロイダルシリカの組み合わせであ
る請求項2記載の顆粒剤。(3) The granule according to claim 2, wherein the water-insoluble inorganic binder is a combination of synthetic aluminum silicate and colloidal silica or a combination of magnesium aluminate metasilicate and colloidal silica.
である請求項1記載の顆粒剤。(4) The granule according to claim 1, wherein the oral medicinal ingredient is water-insoluble or poorly water-soluble.
グリチルレチン酸、ジヒドロコレステロール、クロルヘ
キシジン、エピジヒドロコレステロール、イソプロピル
メチルフェノール、トリクロロカルバニリド、ハロカル
バン及びヒノキチオールからなる群より選ばれる1種又
は2種以上である請求項4記載の顆粒剤。(5) Oral medicinal ingredients include azulene, vitamin E, β-
The granule according to claim 4, which is one or more selected from the group consisting of glycyrrhetinic acid, dihydrocholesterol, chlorhexidine, epidihydrocholesterol, isopropylmethylphenol, trichlorocarbanilide, halocarban, and hinokitiol.
記載の歯磨剤。(7) Claim 6, wherein the content of the granules is 1 to 50% by weight.
Toothpaste listed.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP7115490A JP2857789B2 (en) | 1990-03-20 | 1990-03-20 | Toothpaste |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP7115490A JP2857789B2 (en) | 1990-03-20 | 1990-03-20 | Toothpaste |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH03271215A true JPH03271215A (en) | 1991-12-03 |
JP2857789B2 JP2857789B2 (en) | 1999-02-17 |
Family
ID=13452416
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP7115490A Expired - Fee Related JP2857789B2 (en) | 1990-03-20 | 1990-03-20 | Toothpaste |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP2857789B2 (en) |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000053154A1 (en) * | 1999-03-10 | 2000-09-14 | 3M Espe Ag | Subgingival treatment by powder jet |
WO2001072273A3 (en) * | 2000-03-24 | 2002-04-11 | 3M Espe Ag | Supragingival powder spraying |
US6689342B1 (en) | 2002-07-29 | 2004-02-10 | Warner-Lambert Company | Oral care compositions comprising tropolone compounds and essential oils and methods of using the same |
US6787675B2 (en) | 2002-07-29 | 2004-09-07 | Warner-Lambert Company | Substituted tropolone compounds, oral care compositions containing the same and methods of using the same |
WO2005000260A1 (en) * | 2003-06-27 | 2005-01-06 | Lion Corporation | Dentifrice composition |
JP2007099701A (en) * | 2005-10-05 | 2007-04-19 | Kao Corp | Oral cavity composition |
JP2007126421A (en) * | 2005-11-07 | 2007-05-24 | Kao Corp | Composition for oral cavity application |
JP2009062305A (en) * | 2007-09-05 | 2009-03-26 | Kao Corp | Method for producing dentifrice granule containing non-cationic microbicide |
JP2009102274A (en) * | 2007-10-24 | 2009-05-14 | Kao Corp | Method for producing dentifrice granule containing non-cationic germicide |
JP2009102273A (en) * | 2007-10-24 | 2009-05-14 | Kao Corp | Method for producing dentifrice granule containing non-cationic germicide |
JP2009196987A (en) * | 2008-01-23 | 2009-09-03 | Kao Corp | Tooth paste composition for periodontal disease |
WO2013191226A1 (en) * | 2012-06-20 | 2013-12-27 | 花王株式会社 | Method for producing granules for teeth polishing agent |
JP2014024837A (en) * | 2012-06-20 | 2014-02-06 | Kao Corp | Producing method of dentifrice granule |
JP2014094923A (en) * | 2012-11-12 | 2014-05-22 | Kao Corp | Granule for toothpaste and toothpaste containing it |
JP2015010044A (en) * | 2013-06-27 | 2015-01-19 | 花王株式会社 | Dentifrice |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH01299211A (en) * | 1988-05-25 | 1989-12-04 | Kao Corp | Dentifrice |
-
1990
- 1990-03-20 JP JP7115490A patent/JP2857789B2/en not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH01299211A (en) * | 1988-05-25 | 1989-12-04 | Kao Corp | Dentifrice |
Cited By (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6648644B1 (en) | 1999-03-10 | 2003-11-18 | Espe Dental Ag | Subgingival treatment by powder jet |
WO2000053154A1 (en) * | 1999-03-10 | 2000-09-14 | 3M Espe Ag | Subgingival treatment by powder jet |
WO2001072273A3 (en) * | 2000-03-24 | 2002-04-11 | 3M Espe Ag | Supragingival powder spraying |
US7083411B2 (en) | 2000-03-24 | 2006-08-01 | 3M Espe Ag | Tooth cleaning powders and methods of use thereof |
US6689342B1 (en) | 2002-07-29 | 2004-02-10 | Warner-Lambert Company | Oral care compositions comprising tropolone compounds and essential oils and methods of using the same |
US6787675B2 (en) | 2002-07-29 | 2004-09-07 | Warner-Lambert Company | Substituted tropolone compounds, oral care compositions containing the same and methods of using the same |
US6924398B2 (en) | 2002-07-29 | 2005-08-02 | Warner-Lambert Company Llc | Substituted tropolone compounds, oral care compositions containing the same and methods of using the same |
WO2005000260A1 (en) * | 2003-06-27 | 2005-01-06 | Lion Corporation | Dentifrice composition |
JP2007099701A (en) * | 2005-10-05 | 2007-04-19 | Kao Corp | Oral cavity composition |
JP4704190B2 (en) * | 2005-11-07 | 2011-06-15 | 花王株式会社 | Oral composition |
JP2007126421A (en) * | 2005-11-07 | 2007-05-24 | Kao Corp | Composition for oral cavity application |
JP2009062305A (en) * | 2007-09-05 | 2009-03-26 | Kao Corp | Method for producing dentifrice granule containing non-cationic microbicide |
JP2009102273A (en) * | 2007-10-24 | 2009-05-14 | Kao Corp | Method for producing dentifrice granule containing non-cationic germicide |
JP2009102274A (en) * | 2007-10-24 | 2009-05-14 | Kao Corp | Method for producing dentifrice granule containing non-cationic germicide |
JP2009196987A (en) * | 2008-01-23 | 2009-09-03 | Kao Corp | Tooth paste composition for periodontal disease |
JP2014094959A (en) * | 2008-01-23 | 2014-05-22 | Kao Corp | Tooth paste composition for periodontal disease |
WO2013191226A1 (en) * | 2012-06-20 | 2013-12-27 | 花王株式会社 | Method for producing granules for teeth polishing agent |
JP2014024837A (en) * | 2012-06-20 | 2014-02-06 | Kao Corp | Producing method of dentifrice granule |
CN104394833A (en) * | 2012-06-20 | 2015-03-04 | 花王株式会社 | Method for producing granules for teeth polishing agent |
TWI595887B (en) * | 2012-06-20 | 2017-08-21 | Kao Corp | Dental powder granule manufacturing method |
JP2014094923A (en) * | 2012-11-12 | 2014-05-22 | Kao Corp | Granule for toothpaste and toothpaste containing it |
JP2015010044A (en) * | 2013-06-27 | 2015-01-19 | 花王株式会社 | Dentifrice |
Also Published As
Publication number | Publication date |
---|---|
JP2857789B2 (en) | 1999-02-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5213790A (en) | Methods of reducing plaque and gingivitis with reduced staining | |
US5145666A (en) | Methods of reducing plaque and gingivitis with reduced staining | |
US5004597A (en) | Oral compositions comprising stannous flouride and stannous gluconate | |
RU2465887C2 (en) | Compositions for oral cavity care and their application | |
CA2089731C (en) | Antimicrobial toothpaste | |
JPH03271215A (en) | Drug-containing granule and dentifrice containing the same | |
US4272513A (en) | Stabilized oral composition | |
JPH1017445A (en) | Composition for oral cavity and its production | |
CA2534963A1 (en) | Oral and dental hygiene product | |
JP2000154127A (en) | Composition for oral cavity | |
TW200927184A (en) | Dentifrice composition containing silicone oil beads | |
JPH08169813A (en) | Dentifrice composition | |
JP3065675B2 (en) | Granules and oral compositions containing the same | |
WO1999033437A1 (en) | Tooth cleaning composition in tablet form | |
GB2151478A (en) | Antiplaque/antigingivitis compositions | |
JP3815556B2 (en) | Oral composition | |
JP3189549B2 (en) | Oral composition | |
GB2380408A (en) | Oral composition | |
RU2801309C2 (en) | Oral care composition | |
JPH06279247A (en) | Granules containing germicidal agents and tooth paste containing the same | |
CN113710223B (en) | Personal care compositions comprising piperlonglamide and methods of making the same | |
CN114096225B (en) | Oral care compositions comprising Jiang Erchun and methods of making the same | |
JP2000319153A (en) | Composition for oral cavity | |
JP2001172145A (en) | Composition for oral cavity | |
JPH1135438A (en) | Composition for oral cavity |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20071204 Year of fee payment: 9 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20081204 Year of fee payment: 10 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20081204 Year of fee payment: 10 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20091204 Year of fee payment: 11 |
|
LAPS | Cancellation because of no payment of annual fees |